PT-141, or bremelanotide, is a melanocortin-receptor agonist. The prescription product Vyleesi treats acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women; broader libido claims need their own evidence.
Research focus: Sexual desire in a defined clinical population.
Choose a compound to open its research, documentation and calculator.
Vyleesi: acquired, generalized HSDD in eligible premenopausal women.
Official source ↗Mean terminal half-life after a single subcutaneous dose; reported range 1.9–4.0 hours.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗Approved injections are supplied as solutions; do not add diluent. Tablets are not mixed. A separately supplied powder requires its own formulation documentation.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗The label instructions below apply to the named prescription products and their indications. A matching peptide name on another vial does not establish an equivalent formulation.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Product-specific human evidence and US prescribing information.
Other names you may encounter: Bremelanotide.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
Contraindicated with uncontrolled hypertension or known cardiovascular disease. These instructions apply to the named prescription product.
These amounts belong to different attempts and individuals, rather than repeated administrations on one day.
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Discuss the specific concern, other medicines and relevant health conditions with the treating clinician; the goal and eligible population matter.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.